Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 213

1.

Management of a tracheoesophageal fistula in a patient with AIDS.

Cabañero A, Dronda F, Saldaña D, Hermida JM, Muñoz G, Moreno S.

Asian Cardiovasc Thorac Ann. 2017 Mar;25(3):226-228. doi: 10.1177/0218492317696374. Epub 2017 Jan 1.

PMID:
28325073
2.

Frailty and physical function in older HIV-infected adults.

Brañas F, Jiménez Z, Sánchez-Conde M, Dronda F, López-Bernaldo De Quirós JC, Pérez-Elías MJ, Miralles P, Ramírez M, Moreno A, Berenguer J, Moreno S.

Age Ageing. 2017 May 1;46(3):522-526. doi: 10.1093/ageing/afx013.

PMID:
28203694
3.

Changing Incidence and Risk Factors for Kaposi Sarcoma by Time Since Starting Antiretroviral Therapy: Collaborative Analysis of 21 European Cohort Studies.

Cancer Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord.

Clin Infect Dis. 2016 Nov 15;63(10):1373-1379. Epub 2016 Aug 17.

4.

Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study).

Perez-Molina JA, Rubio R, Rivero A, Pasquau J, Suárez-Lozano I, Riera M, Estébanez M, Palacios R, Sanz-Moreno J, Troya J, Mariño A, Antela A, Navarro J, Esteban H, Moreno S; GeSIDA 7011 Study Group.

J Antimicrob Chemother. 2017 Jan;72(1):246-253. Epub 2016 Sep 13.

PMID:
27629070
5.

Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy.

Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, van Lunzen J, Corbelli GM, Estrada V, Geretti AM, Beloukas A, Asboe D, Viciana P, Gutiérrez F, Clotet B, Pradier C, Gerstoft J, Weber R, Westling K, Wandeler G, Prins JM, Rieger A, Stoeckle M, Kümmerle T, Bini T, Ammassari A, Gilson R, Krznaric I, Ristola M, Zangerle R, Handberg P, Antela A, Allan S, Phillips AN, Lundgren J; PARTNER Study Group.

JAMA. 2016 Jul 12;316(2):171-81. doi: 10.1001/jama.2016.5148. Erratum in: JAMA. 2016 Aug 9;316(6):667. Erratum in: JAMA. 2016 Nov 15;316(19):2048.

PMID:
27404185
6.

Relationship between plasma bilirubin level and oxidative stress markers in HIV-infected patients on atazanavir- vs. efavirenz-based antiretroviral therapy.

Estrada V, Monge S, Gómez-Garre MD, Sobrino P, Masiá M, Berenguer J, Portilla J, Viladés C, Martínez E, Blanco JR; CoRIS and the HIV Biobank integrated in the Spanish AIDS Research Network.

HIV Med. 2016 Oct;17(9):653-61. doi: 10.1111/hiv.12368. Epub 2016 Mar 3.

PMID:
26935006
7.

Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013.

Sobrino-Vegas P, Moreno S, Rubio R, Viciana P, Bernardino JI, Blanco JR, Bernal E, Asensi V, Pulido F, del Amo J, Hernando V; Cohorte de la Red de Investigación en Sida, Spain.

J Infect. 2016 May;72(5):587-96. doi: 10.1016/j.jinf.2016.01.017. Epub 2016 Feb 24.

8.

Development and Validation of an HIV Risk Exposure and Indicator Conditions Questionnaire to Support Targeted HIV Screening.

Elías MJ, Gómez-Ayerbe C, Elías PP, Muriel A, de Santiago AD, Martinez-Colubi M, Moreno A, Santos C, Polo L, Barea R, Robledillo G, Uranga A, Espín AC, Quereda C, Dronda F, Casado JL, Moreno S.

Medicine (Baltimore). 2016 Feb;95(5):e2612. doi: 10.1097/MD.0000000000002612.

9.

The Burden of Neglected HIV-2 and HTLV-1 Infections in Spain.

Treviño A, Caballero E, de Mendoza C, Aguilera A, Pirón M, Soriano V; Spanish HIV-2/HTLV Study Group.

AIDS Rev. 2015 Oct-Dec;17(4):212-9. Review.

PMID:
26616845
10.

Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.

Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miró JM, Ferrer E, Justice A, Gandhi N, Bucher HC, Furrer H, Moreno S, Monge S, Touloumi G, Pantazis N, Sterne J, Young JG, Meyer L, Seng R, Dabis F, Vandehende MA, Pérez-Hoyos S, Jarrín I, Jose S, Sabin C, Hernán MA; HIV-CAUSAL Collaboration.

Lancet HIV. 2015 Aug;2(8):e335-43. doi: 10.1016/S2352-3018(15)00108-3. Epub 2015 Jul 7.

11.

Progressive multifocal leukoencephalopathy mimicking milliary CNS tuberculosis.

Corral I, Quereda C, Dronda F, Navas E, Hermida JM, Moreno C, Martínez-San-Millán J.

J Neurovirol. 2015 Dec;21(6):691-3. doi: 10.1007/s13365-015-0367-6. Epub 2015 Aug 5. No abstract available.

PMID:
26242918
12.

Brief Report: Reduced Cell-Associated HTLV-2 DNA in Antiretroviral Treated HIV-1-HCV-Coinfected Patients Who Either Received Interferon-α/Ribavirin-Based Hepatitis C Therapy or Had Spontaneous HCV RNA Clearance.

Abad-Fernández M, Dronda F, Moreno A, Casado JL, Pérez-Elías MJ, Quereda C, Moreno S, Vallejo A.

J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):286-90. doi: 10.1097/QAI.0000000000000608.

PMID:
26181704
13.

Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.

Perez-Molina JA, Rubio R, Rivero A, Pasquau J, Suárez-Lozano I, Riera M, Estébanez M, Santos J, Sanz-Moreno J, Troya J, Mariño A, Antela A, Navarro J, Esteban H, Moreno S; GESIDA 7011 Study Group.

Lancet Infect Dis. 2015 Jul;15(7):775-84. doi: 10.1016/S1473-3099(15)00097-3. Epub 2015 Jun 7. Erratum in: Lancet Infect Dis. 2015 Sep;15(9):998.

PMID:
26062881
14.

Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial.

Arribas JR, Girard PM, Landman R, Pich J, Mallolas J, Martínez-Rebollar M, Zamora FX, Estrada V, Crespo M, Podzamczer D, Portilla J, Dronda F, Iribarren JA, Domingo P, Pulido F, Montero M, Knobel H, Cabié A, Weiss L, Gatell JM; OLE/RIS-EST13 Study Group.

Lancet Infect Dis. 2015 Jul;15(7):785-92. doi: 10.1016/S1473-3099(15)00096-1. Epub 2015 Jun 7. Erratum in: Lancet Infect Dis. 2015 Aug;15(8):875.

PMID:
26062880
15.

Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.

HIV-CAUSAL Collaboration, Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA.

Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167. Epub 2015 Jan 6.

16.

Delayed liver fibrosis in HTLV-2-infected patients co-infected with HIV-1 and hepatitis C virus with suppressive antiretroviral therapy.

Abad-Fernández M, Moreno A, Dronda F, del Campo S, Quereda C, Casado JL, Pérez-Elías MJ, Moreno S, Vallejo A.

AIDS. 2015 Feb 20;29(4):401-9. doi: 10.1097/QAD.0000000000000555.

PMID:
25565497
17.

Incidence of hepatitis C virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: increasing rates of HCV diagnosis but not of HCV seroconversions.

Sobrino-Vegas P, Monge Corella S, Serrano-Villar S, Gutiérrez F, Blanco JR, Santos I, del Romero J, Segura F, Portilla J, Guillén SM, del Amo J; CoRIS.

PLoS One. 2014 Dec 30;9(12):e116226. doi: 10.1371/journal.pone.0116226. eCollection 2014.

18.

Comparison of the prognostic value of liver biopsy and FIB-4 index in patients coinfected with HIV and hepatitis C virus.

Berenguer J, Zamora FX, Aldámiz-Echevarría T, Von Wichmann MA, Crespo M, López-Aldeguer J, Carrero A, Montes M, Quereda C, Téllez MJ, Galindo MJ, Sanz J, Santos I, Guardiola JM, Barros C, Ortega E, Pulido F, Rubio R, Mallolas J, Tural C, Jusdado JJ, Pérez G, Díez C, Álvarez-Pellicer J, Esteban H, Bellón JM, González-García J; Grupo de Estudio del SIDA (GESIDA) HIV/HCV Cohort Study Group.

Clin Infect Dis. 2015 Mar 15;60(6):950-8. doi: 10.1093/cid/ciu939. Epub 2014 Nov 24.

PMID:
25422386
19.

Altered metabolism of gut microbiota contributes to chronic immune activation in HIV-infected individuals.

Vázquez-Castellanos JF, Serrano-Villar S, Latorre A, Artacho A, Ferrús ML, Madrid N, Vallejo A, Sainz T, Martínez-Botas J, Ferrando-Martínez S, Vera M, Dronda F, Leal M, Del Romero J, Moreno S, Estrada V, Gosalbes MJ, Moya A.

Mucosal Immunol. 2015 Jul;8(4):760-72. doi: 10.1038/mi.2014.107. Epub 2014 Nov 19.

PMID:
25407519
20.

Incremental cost per newly diagnosed HIV infection (NDHI): routine (RTS), targeted (TTS), and current clinical practice testing strategies (CPTS).

Gomez-Ayerbe C, Elías MJ, Muriel A, Elías PP, Cano A, Diaz A, Moreno A, Casado JL, Santos C, Martinez-Colubi M, Uranga A, Dronda F, Moreno S.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19606. doi: 10.7448/IAS.17.4.19606. eCollection 2014.

Supplemental Content

Loading ...
Support Center